ArticleNature medicine2026
Evidence of monkeypox virus clade IIb lineage A.2.2 in the Republic of the Congo and co-circulation of clade Ia, Ib and clade IIb.
Article in Nature medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Discovery of the nucleoside analogue FMAU as a broad-spectrum anti-orthopoxvirus inhibitor in vitro and in vivo using a structure-guided hit expansion strategy.Emerging microbes & infections · 2026Article
- A comprehensive overview of monkeypox virus disease.Tropical medicine and health · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In 2022, monkeypox virus (MPXV) clade IIb emerged resulting in a global epidemic driven by human-to-human transmission, mostly through sexual contact mainly among the population of men who have sex with men. To date, published data on the circulation of MPXV clade IIb in the central African region are absent. Here we describe a case of laboratory-confirmed mpox clade IIb lineage A2.2 in Pointe-Noire, the second largest city of the Republic of the Congo. Whole-genome phylogenetic analysis placed the MPXV in clade IIb, lineage A.2.2 currently emerging in West Africa, in particular Sierra Leone. An additional 16 cases of clade Ia, 32 cases of clade Ib and one additional introduction of clade IIb were identified by passive surveillance in the Republic of the Congo in 2025. The detection of clade IIb mpox marks the third distinct MPXV clade and lineage co-circulating in the human population, together with clade Ia and Ib. This underscores the need for improved surveillance and diagnostic strategies to identify the respective clade and lineage circulating in the human population. Strengthening of regional capacity for case detection, contact-tracing, public health measures and affordable vaccines are urgently needed to reduce the global risk for both clade I and clade II MPXV.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.